Product Description
Tranexamic acid is used to treat heavy menstrual bleeding in women. This medicine may be used by teenage females, but is not intended for use before the start of menstruation. Tranexamic acid is an antifibrinolytic agent. It works by blocking the breakdown of blood clots, which prevents bleeding. (Sourced from: https://www.mayoclinic.org/drugs-supplements/tranexamic-acid-oral-route/description/drg-20073517)
Mechanisms of Action: Fibrinolysis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral,Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: Croatia, Germany, Hungary, Nigeria, Pakistan, Romania, Spain, Tanzania, United States, Zambia
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia|Brain Hemorrhage, Traumatic|Hip Fracture|Injuries/wounds Unspecified|Sarcoma
Phase 2: Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
2005-005103-41 | P2 |
Completed |
Unknown |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
STOP-MSU | P2 |
Completed |
Stroke |
2023-05-28 |
2025-05-16 |
Treatments |
|
PRADO | P2 |
Active, not recruiting |
Unknown |
2022-05-07 |
2025-05-06 |
Treatments |
|
TIC-TOC | P3 |
Not yet recruiting |
Brain Hemorrhage, Traumatic |
2030-03-31 |
2023-11-16 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
|
TATRA | P3 |
Not yet recruiting |
Anemia |
2025-11-30 |
2024-05-15 |
Primary Endpoints|Treatments |
|
HYL-P004-003 | P3 |
Recruiting |
Injuries/wounds Unspecified |
2024-12-27 |
4% |
2024-08-02 |
|
HYL-P004-003 | P3 |
Recruiting |
Injuries/wounds Unspecified |
2024-06-27 |
4% |
2025-05-02 |
Treatments |
WOMAN-2 | P3 |
Completed |
Anemia |
2023-09-20 |
2024-01-11 |
||
NCT05047133 | P3 |
Recruiting |
Hip Fracture |
2022-07-01 |
2024-03-06 |
||
UTOTXA_2016 | P3 |
Active, not recruiting |
Sarcoma |
2019-01-31 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
---|---|---|
06/10/2025 |
News Article |
From the Makers Of Tree Hut Comes bdy. - A New Era of Self-Care |
04/08/2025 |
News Article |
Southeast Asian Founder Launches DEAU, a Groundbreaking Skincare Brand from Japan Reimagined for Melanin-Rich Skin |
03/19/2025 |
News Article |
Nexus Pharmaceuticals Launches Tranexamic Acid |
03/11/2025 |
News Article |
HSS Presents Innovative Research Aimed at Faster Recovery After Knee Surgery at AAOS Annual Meeting |